focus on

• Exploiting Cancer Stem Cells
• Combining Molecular Targeted Therapies
• Epigenetics and Emerging Targets
• Companion Diagnostics and Biomarkers
• Regulatory Pathways and Perspectives

NEW FRONTIERS IN CANCER DRUG DEVELOPMENT

Innovations in Discovery Science, Translational Research and Cancer Clinical Trials

Conference Keynote
From Empiric to Specific: How Can We Translate Science into Cancer Treatments and Get it Right More Reliably?
George D. Demetri, M.D.  
Director, Ludwig Center at Dana-Farber/Harvard Cancer Center  
Center for Sarcoma and Bone Oncology  
Dana-Farber Cancer Institute

Featured Presentation
The Evolving Treatment Paradigm in Multiple Myeloma
Kenneth C. Anderson, M.D.  
Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute and  
Kraft Family Professor of Medicine, Harvard Medical School

Debate and Discussion:
Point:  
The current approach to first-in-class innovation in oncology isn’t working

Counterpoint:  
Novel target discovery platforms are feeding innovation in oncology

Plenary Keynote
Global Pharma Innovator: Daiichi Sankyo’s Challenge to Build a Competitive Pharmaceutical Company in the Global Market
Takashi Shoda  
President and CEO,  
Daiichi Sankyo Co., Ltd., Japan

Gold Sponsor
In Conjunction with
www.drugdisc.com/Cancer

Register Early and Save Up To $300

In Conjunction with
The failure rate for cancer drug approvals is high relative to other therapeutic areas because of poor preclinical models of human cancer, challenges in demonstrating efficacy in the clinic, and the complexity of clinical trial design for cancer drugs. Bridging the gap between discovery science, clinical science and clinical trial design to improve translation from preclinical to clinical is crucial to increase cancer drug approval rates. This conference will explore many of the new frontiers in cancer drug development that companies are exploring to fill the innovation gap including new advances in cancer stem cell research and emerging data from combinations of molecular targeted cancer agents that are showing promise. Practical examples of the development of biomarkers and companion diagnostics to inform cancer drug development strategies and to stratify and select patient populations for cancer clinical trials will also be presented including a discussion of the regulatory pathway and FDA position relative to cancer drug development.

**Scientific Advisory Board**

Helen Chen, M.D., Associate Branch Chief, Cancer Therapy Evaluation Program, National Cancer Institute

Kevin P. Foley, Ph.D., Director of In Vivo Pharmacology, Synta Pharmaceuticals Corp.

William Hait, M.D., Ph.D., Senior Vice President, Worldwide Head, Oncology/Hematology R&D, Ortho Biotech Oncology - A J&J Co.

John Herrmann, Ph.D., Executive Director, Search & Evaluation (Oncology), EMD Serono (U.S. Division of Merck Serono)

Julia Y. Ljubimova, M.D., Ph.D., Director of Drug Delivery and Nanomedicine, Department of Neurosurgery, Cedars-Sinai Medical Center

John Newcomb, Ph.D., Director, Research, Hematology/Oncology Research, Amgen, Inc.

Lyuba Varticovski, M.D., Staff, Cancer Research Center, National Cancer Institute

---

**Who Should Attend and Who You Will Meet:**

Chief Scientific Officers, Vice Presidents, Directors, Managers, Heads of Departments, Group/Team/Project Leaders, Scientists, Investigators and Researchers, Scientific Directors, Chief Medical Officers, Medical Directors working in the following areas:

- Oncology R&D
- Cancer Biology
- Hematology
- Drug Discovery
- R&D
- Lead Discovery
- Genetics
- Pharmacogenomics
- Biomarkers
- Translational Research
- Clinical Science/R&D
- Drug Delivery
- Antibody Discovery
- Protein Sciences
- Exploratory Clinical Development
- Medical Sciences

---

**Drug Discovery & Development Week**

The New Frontiers in Cancer Drug Development conference is part of Drug Discovery & Development Week in Boston, MA. This week long event features five targeted scientific conferences enabling you to:

- **Meet face-to-face** with leading scientists, group leaders and executives who are seeking solutions for their specific drug discovery and development challenges.

- **Learn practical strategies** and forward-looking approaches to help you accelerate small molecules, antibody therapeutics and oligonucleotide therapeutics from early discovery to the clinic.

**Get the Most out of your Budget: Purchase an All-Access Conference Pass**

<table>
<thead>
<tr>
<th>Co-Located Conferences</th>
<th>Monday, August 3</th>
<th>Tuesday, August 4</th>
<th>Wednesday, August 5</th>
<th>Thursday, August 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Next Wave of Antibody Therapeutics</td>
<td>Main Conference</td>
<td>Main Conference</td>
<td>Post-Conference Workshop</td>
<td></td>
</tr>
<tr>
<td>Oligonucleotide Therapeutics: From Concept to Implementation</td>
<td>Main Conference</td>
<td>Main Conference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Frontiers in Cancer Drug Development</td>
<td>Pre-Conference Workshop</td>
<td>Main Conference</td>
<td>Main Conference</td>
<td></td>
</tr>
<tr>
<td>Targets in Context: Linking Targets to Disease</td>
<td>Pre-Conference PM Workshop</td>
<td>Main Conference</td>
<td>Main Conference</td>
<td></td>
</tr>
<tr>
<td>Drug Safety Strategies to De-Risk Compounds</td>
<td>Pre-Conference Workshop</td>
<td>Main Conference</td>
<td>Main Conference</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cocktail Reception in Exhibit Hall</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Visit www.drugdisc.com for detailed agendas of all co-located conferences and workshops.
Biomarkers and Companion Diagnostics for Cancer Therapy

1:00 Workshop Chair Opening Remarks
Richard A. Bender, M.D., Vice President and Chief Medical Officer, Agendia BV

1:10 Companion Diagnostics and Biomarkers in Developing Cancer Therapeutics: The Emergence of Targeted Therapies and Strategies to Improve Clinical Trial Design
Functional genomics and proteomics approaches provide the basis for transforming medicine from the current disease-centric to a patient-centric approach. As the technologies become validated, clinical applications emerge that change drug development and will lead to individualized medicine. Strategies to improve cancer clinical trial design and to identify targeted therapies and biomarkers will be presented.
Towia A. Libermann, Associate Professor of Medicine, Beth Israel Deaconess Medical Center and Director, BIDMC Genomics and Proteomics Center

1:40 VEGF Pathway Response Biomarkers Using Population-based Preclinical Models
We present a unique preclinical platform that queries entire populations of genetically engineered tumor models for drug response. Like human tumors, these tumors exhibit variation in response to our phase 2 VEGFRI AV-951. The resulting novel response biomarker derived from this platform is currently being evaluated in ongoing clinical studies.
Murray O. Robinson, Ph.D., Senior Vice President, Oncology, AVEO Pharmaceuticals, Inc.

2:10 Successfully Validating, Commercializing and Fostering Adoption of Novel Biomarkers: Three Different Issues, One Common Goal
Richard A. Bender, M.D., Vice President and Chief Medical Officer, Agendia BV

2:40 Networking Break in Exhibit & Poster Hall

3:15 Biomarkers from Research to the Clinic
Biomarkers can have a great impact in clinical trials by increasing the efficacy of the trial and decreasing the number of patients enrollment. The talk will focus on how biomarkers can be found in preclinical samples, how those biomarkers are validated and how they can be applied to clinical trials. Two types of biomarkers will be presented, pharmacodynamic biomarkers, that are useful for finding the right dose for the patients, and predictive biomarkers, which will find the patients that most likely will benefit from that specific compound. Several examples of each type of biomarker will be presented with the results from clinical trials. Of these biomarkers the predictive biomarkers are the most likely to be developed into companion diagnostic tools.
J. Suso Platero, Ph.D., Director Oncology Biomarkers, Centocor R&D, Johnson & Johnson

3:45 Biomarker Strategies for Developing Novel Cancer Therapeutics
Today's oncology candidate drugs target molecular entities and pathways that can be assessed using sophisticated enabling technologies. As markers, these can be used to demonstrate proof of concept, stratify/select clinical trial subjects, predict response and, occasionally, as a companion diagnostic. Approaches to managing the development challenges these present will be reviewed.
John C Bloom, Ph.D., Executive Director, Diagnostic and Experimental Medicine, Eli Lilly and Company

4:15 Strategic Discussion Group
The Reality of Implementation and Regulatory Pathways for Biomarkers and Companion Diagnostics in Cancer: What is the Right Approach? For biomarkers:
- What is the regulatory path for biomarkers and companion diagnostics in cancer?
- When to engage diagnostic companies to transition a biomarker to a companion diagnostic?
- If a companion diagnostic is developed, will people use it? What is the reality of implementation of companion diagnostics in the clinical setting? Moderators: Richard A. Bender, M.D., Vice President and Chief Medical Officer, Agendia BV
John C Bloom, Ph.D., Executive Director, Diagnostic and Experimental Medicine, Eli Lilly and Company

5:00 Cocktail Reception in Exhibit & Poster Hall

Visit www.drugdisc.com/Cancer for up-to-date information on this event
8:40 Targeting Cancer Stem Cells
Cancer stem cells are thought to mediate tumor initiation, metastasis, and recurrence. We have isolated and characterized CSCs from a variety of major tumor types and have found that these cells are preferentially resistant to many current therapies. As part of our effort to develop novel agents targeting CSCs, we have developed an anti-DLL4 antibody that blocks Notch signaling. Anti-DLL4 inhibits tumor growth through multiple mechanisms including a reduction in CSC frequency.

Timothy Hoey, Ph.D., Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.

9:15 Selection and Expansion of Stem-like Cells from Solid Tumors Based on Growth and Survival Properties: Cell Surface Antigens Useful as Drug Targets
The CSC hypothesis has important implications for drug development and cancer treatment. Most CSC studies use cell populations enriched using prospectively defined markers. We have used defined media to select subpopulations of cells from solid tumors, including colon and prostate, which are capable of self-renewal and form well differentiated tumors. These cell lines can be used to develop and screen drug candidates and to further characterize gene and cell surface marker expression. Preclinical and clinical data from two projects…a novel target/Mab and a set of novel Mabs to a known target… that we find on our stem or progenitor cells and cancer stem cells will be presented.

Jenny P. Mather, M.D., Ph.D., Senior Vice President, Cancer Stem Cell Research, MacroGenics, Inc.

9:50 Developing Drug Candidates Directed to Cancer Stem Cell Targets: Preclinical and Clinical Update
Stemline Therapeutics, a clinical stage biopharmaceutical company, is developing a broad portfolio of small molecule and biologic compounds directed to cancer stem cell targets of both solid and hematological cancers. Stemline has built its pipeline through a combination of acquisition and internal discovery. Stemline has also developed several novel cancer stem cell focused drug discovery platforms, including a proprietary high throughput screen (“StemScreen™”), which the Company has utilized to identify multiple anti-cancer stem cell compounds. Emerging data from the Company's multiple cancer stem cell projects, including its IL-3R and Notch directed programs as well as its discovery platform, will be presented.

Ivan Bergstein, M.D., CEO, Stemline Therapeutics, Inc.

10:20 Networking Refreshment Break in Poster & Exhibit Hall

11:00 Targeting the Hedgehog Pathway in Cancer Treatment
Hedgehog (Hh) pathway activity plays a crucial role in embryonic development and tissue homeostasis. Mutations of the pathway effector genes and increased Hh ligand expression have been identified in human tumors. Inhibition of the Hh pathway has resulted in clinical benefit for patients with tumors driven by activated Hh pathway.

Chia Portera, M.D., Ph.D., Assistant Medical Director, Exploratory Clinical Development, Genentech BioOncology

11:30 Strategic Discussion Group: Cancer Stem Cells
• Is there a difference between a cancer stem cell and a tumor initiating cell?
• Defining molecular and functional characteristics of cancer stem cells
• Understanding mechanisms of resistance of cancer stem cells
• What is the best way to target tumor stem cells?

Moderator: Lyudmila Varticovski, M.D., Staff, Cancer Research Center, National Cancer Institute Panelsists:
Timothy Hoey, Ph.D., Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.
Jenny P. Mather, M.D., Ph.D., Senior Vice President, Cancer Stem Cell Research, MacroGenics, Inc.
Ivan Bergstein, M.D., CEO, Stemline Therapeutics, Inc.
Chia Portera, M.D., Ph.D., Assistant Medical Director, Exploratory Clinical Development, Genentech BioOncology

12:00 Conference Keynote
(Open to all attendees and exhibit hall visitors)
From Empiric to Specific: How Can We Translate Science into Cancer Treatments and Get It Right More Reliably?
Conventional anticancer cytotoxic therapy is highly empiric, and while a subset of patients benefit, the relative therapeutic index of these agents is amongst the lowest of any systemic drugs used in medicine. By understanding the huge variety of cancers, and validating more fully the leads coming from basic discovery biology, clinical oncology stands poised to recreate the field of translational and clinical research in a way that takes advantage of “personalized medicine” approaches to increase the success and the relative impact of new investigational therapies. Lessons learned from the development of successful “targeted therapies” such as imatinib, sunitinib, nilotinib, and dasatinib, as well as other targeted agents, will be summarized to help point the way in which collaborative research models can be developed which support rapid discovery and development of highly effective new anticancer agents based on the best science and clinical insights.

George D. Demetri, M.D., Director, Ludwig Center at Dana-Farber/Harvard Cancer Center and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute

12:30 Networking Luncheon in Exhibit & Poster Hall

New Approaches for Targeting Cancer
1:45 The Lin28 Oncogene and Pluripotency Factor is a Potential Target in Cancer Stem Cells
Members of the let-7 microRNA family are emerging as promoters of differentiation in development and as tumor suppressors in cancer. The microRNA-binding proteins Lin28 and Lin28B were recently identified as potent suppressors of let-7 processing, positioning them as oncogenes and stem cell reprogramming factors. Indeed, several reports have demonstrated the importance of let-7 and Lin28 in human cancer and normal stem cell function. Exploring this intersection of microRNAs, cancer, and pluripotency opens new avenues for the pharmacologic enhancement of regeneration and suppression of cancer stem cells.

Hao Zhu, M.D., Ph.D., Post-Doctoral Fellow in the lab of George Q. Daley, Department of Hematology/Oncology, Dana-Farber Cancer Institute and Children's Hospital of Boston

2:10 A New Paradigm for Translational Cancer Research: Targeting Endocrine Factors and Real Human Tumors
This presentation will discuss research focused on identifying systemic and endocrine factors that contribute to tumor progression. As a consequence of this work, an in vivo model system to study the growth of human tumor surgical specimens that otherwise did not form xenografts, has been developed. Ultimately, the ability to target endocrine factors and to study real human tumor specimens holds the hope of designing new cancer therapies.

Sandra S. McAllister, Ph.D., Assistant Professor of Medicine, Hematology Division, Brigham & Women's Hospital and Harvard Medical School

2:35 AMG 386, an Anti-Angiogenic Agent Targeting the Angiopoietin-Tie2 Pathway
This presentation will provide preclinical and clinical updates on the status of AMG 386, a perfluorocarbon-Fc fusion protein that binds to angiopoietin-1 and 2. It is being investigated as a cancer treatment and is currently in phase 2 clinical trials.

Jon Oliner, M.D., Ph.D., Scientific Director, Oncology Research, Amgen, Inc.

3:00 Targeting Chromatin Modifying Enzymes as an Epigenetic Therapy for Cancer
Deregulation of gene expression caused by genetic and epigenetic mechanisms that affect key cellular control pathways is a hallmark of human cancers. Chromatin modifying enzymes like histone and DNA methyltransferases have been identified as important epigenetic regulators of chromatin function and resultant changes in gene expression. The pharmacological inhibition of these enzymes by small molecule compounds offers an attractive therapeutic approach in which changes of the epigenetic modification landscape cause an inactivation of cancer-related genes and reactivation of tumor suppressor genes.

Patrick Trojer, Ph.D., Senior Scientist, Constellation Pharmaceuticals

3:25 Technology Workshop: Genotype-correlated Photodynamic Drug Discovery- OncoPanel™
OncoPanel comprises of a compendium of a large panel of human tumor-derived cell lines from different origins with broad genetic heterogeneity and a sensitive High Content Analysis method for comparing proliferation or cytotoxicity across genotypes. We have developed a panel of 240 human cell lines with genetic information available on the genome copy number, miRNA expression data and genotyping. The media and culture conditions, cell fixation and High Content Analysis are standardized and optimized so that the genetic heterogeneity of the cell line will be responsible for the results obtained. We generate simultaneous data for each compound at 10 concentrations in triplicates resulting in precise EC50/ECC50 values for analysis and comparison. Results from a case study will be presented to depict the very robust data quality. Also, data with known inhibitors will be presented using a smaller subset of the cells.

Usha Warrior, Ph.D., Technical Director, In Vitro Pharmacology, MDS Pharma Services
Innovation Starvation in Oncology Drug Development: Implications for R&D Strategies

4:30 POINT: The industry is changing and the current approach to first-in-class innovation in oncology isn’t working.

Is There Evidence that First-in-class Innovation in Oncology is Dwindling?
• How will this impact R&D pipelines, revenues and patients?
• What effects might scarcer innovation have on the competitive landscape in cancer drug development?

John Herrmann, Ph.D., Executive Director, Search & Evaluation (Oncology), EMD Serono (U.S. Division of Merck Serono)

4:55 COUNTERPOINT: Novel target discovery platforms are feeding innovation in oncology

FunctionFIRST: A Novel Antibody/Target Discovery Platform
Unlike traditional drug discovery approaches where an inhibitor is made to a pre-selected target and subsequently tested for efficacy, the FunctionFIRST approach identifies antibodies that inhibit cancer cell but not normal cell viability in vitro and in vivo before target identification. Examples and merits of this strategy will be discussed.

Daniel S. Pereira, Ph.D., Vice President, Head of Research, Pharma Research Toronto, Hoffmann-La Roche Ltd., Canada

5:20 Discussion
5:45 Close of Day One

Attendee Networking Dinner
Join fellow attendees of the New Frontiers in Cancer Drug Development conference for dinner. Space is limited and an additional fee applies. Check box on registration form to sign up.

8:30 Conference Chair Opening Remarks
Helen Chen, M.D., Associate Branch Chief, Cancer Therapy Evaluation Program, National Cancer Institute

8:35 Combination Cancer Therapies and Multi-Targeting Strategies for Novel Therapeutics

Combination of Molecularly Targeted Agents: Opportunities and Challenges
Combination of molecularly targeted agents has the potential to overcome molecular complexity of cancer and improve the therapeutic outcome in patients. Challenges for clinical evaluation of novel combinations are however unprecedented. This presentation will review the critical elements of a rational strategy as well as experience with NCI-sponsored clinical trials for targeted agent combinations. Scientific and intellectual property issues and possible means of overcoming these barriers will be discussed.

Helen Chen, M.D., Associate Branch Chief, Cancer Therapy Evaluation Program, National Cancer Institute

9:05 The Evolving Treatment Paradigm in Multiple Myeloma
Thalidomide, lenalidomide, bortezomb, and Doxil provided the framework for six new FDA approved treatments for multiple myeloma, extending the median survival from three to seven years. Preclinical models are informing rational design of combination of novel and conventional agents to enhance response, overcome drug resistance, and further improve patient outcome.

Kenneth C. Anderson, M.D., Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute and Kraft Family Professor of Medicine, Harvard Medical School

9:35 A Novel Approach to Combination Therapy through Cancer Network Disruption: Curis’ Multi-Targeted Inhibitor Platform
Curis has developed an approach to accomplish the benefits of combination therapy through single small molecule Multi-Target Inhibitors (MTI) based upon novel chemical drug structures. The most advanced drug from the MTI platform, CUDC-101 is a highly potent, first-in-class, small molecule currently in dose escalation Phase 1, designed to specifically and synergistically target HDAC/EGFR/Her-2. The presentation will describe the underlying rationale for the MTI platform and describe preclinical in-vitro and in vivo data, including mechanism of action and demonstration of synergistic effects. The presentation will also present relevant clinical data, including does escalation observations and relevant biomarker data. This case study will exemplify Curis’ multi-targeted approach to cancer drug development and the proposed advantages including aligned PK and potencies, better control of exposure and the promise of enhanced efficacy with a better tolerability and safety profile.

Daniel Passeri, President and CEO, Curis, Inc.

10:05 Interplay Between EGFR-TKI Resistance Mechanisms, EMT Biology and a Rationale for Multi-Targeting
Abstract not available at time of print. Please visit www.drugdisc.com/Cancer for updates.

David M. Epstein, Ph.D., Senior Vice President, Oncology Research, OSI Pharmaceuticals

10:35 Networking Refreshment Break

11:05 The Use of Genetically Engineered Mouse Lung Cancer Models to Assess Effectiveness of Targeted Therapeutic Combinations
To understand genetically the roles of the recently discovered B-RAF, HER2/NEU, KRAS, EGFR, ALK and PI3K mutations in lung cancer, my laboratory has generated various inducible bi-transgenic mice harboring these mutations. We have recently demonstrated that the activations of all these mutants in the lung epithelium are oncogenic in vivo as mice expressing these activated alleles develop lung tumors de novo. We have characterized these mice in detail and are now using them as unique platforms for testing various combination of targeted therapeutics that can produce dramatic responses in each type of these oncogene specific driven lung cancers.

Kwok-Kin Wong, M.D., Ph.D., Assistant Professor, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School

11:35 Bevacizumab in Patients with Previously Treated Glioblastoma
Glioblastoma, a primary brain tumor with a dismal prognosis, is highly vascularized with overexpression of vascular endothelial growth factor (VEGF). In a Phase II study in patients with previously treated glioblastoma, treatment with bevacizumab, an anti-VEGF antibody, has demonstrated efficacy with a durable response rate.

Asha Das, M.D., Medical Director, BioOncology, Genentech

12:05 Strategic Discussion Group

Are Targeted Therapies Better than Non-Targeted Therapies?
• Lessons learned from the targeted therapy approach and what needs to be improved?
• Targeted therapies versus conventional therapies: what does the future hold?
• Combination cancer therapies…which combinations? How can companies work together?
• Approaches to combinations of targeted agents for cancer….can preclinical evaluations be extrapolated into clinical successes?
• What is the intelligent approach to choose multiple intervention points in cancer therapy?

Moderator: William N. Hait, M.D., Ph.D., Senior Vice President, Worldwide Head Oncology/Hematology R&D, Ortho Biotech Oncology R&D, The Johnson & Johnson Family of Companies
**Extrapolating Preclinical Models to the Clinic**

**Discussion Leaders:**
- Murray Robinson, Ph.D., Senior Vice President, Oncology, AVEO Pharmaceuticals, Inc.
- Kevin P. Foley, Ph.D., Director, In Vivo Pharmacology, Synta Pharmaceuticals Corp.

**Strategies to Exploit Epigenetic Mechanisms for Drug Discovery**

**Discussion Leader:** John C Bloom, Ph.D., Executive Director, Diagnostic and Experimental Medicine, Eli Lilly and Company

**Combinations of Novel and Conventional Cancer Agents: Challenges and Opportunities**

**Discussion Leaders:**
- Kenneth C. Anderson, M.D., Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute and Kraft Family Professor of Medicine, Harvard Medical School
- Helen Chen, M.D., Associate Branch Chief, Cancer Therapy Evaluation Program, National Cancer Institute

**Biomarkers and Cancer Drug Development**

**Discussion Leader:** TBA

---

**Venue, Hotel and Travel Information**

**Venue:** World Trade Center Boston, 200 Seaport Blvd., Boston, MA 02210

**Phone:** 617-385-3500 • Fax: 617-385-5090

**Hotel:** The Seaport Hotel, 200 Seaport Boulevard, Boston, MA, 02210

**Phone:** 1-877-SEAPORT OR 1-617-385-4000

**Fax:** 1-617-385-5090 • www.seaportboston.com

IBC Life Sciences has secured a block of discounted sleeping rooms at the Seaport Hotel. Please identify yourself as an IBC Drug Discovery and Development Week participant to qualify for the reduced rate. The discounted rate expires July 1, 2009 but make your reservations as soon as possible as availability is not guaranteed.

Please note:
1. A first and last name non-refundable deposit is required at the time of reservation.
2. Cancellations and changes to a reservation will be accepted without further financial responsibility up until July 20, 2009. Your credit card is subject to being charged for your full reservation if cancellation or changes to a reservation are received after the July 20, 2009 cut off date.

**Additional Registration Information**

Unauthorized solicitation is strictly prohibited at this event and failure to comply could result in revocation of your access privileges. This is a trade only event. For your safety and security, a photo identification and industry related business card are required at the conference check-in to complete your registration.

Program content and speakers subject to change. Children under 18 are not permitted in the exhibit hall under any circumstances. Conference badges are non-transferable and lost badges will not be replaced without payment of the full conference registration fee.

Please note that payment is required in advance of the conference. Please make check(s) (in U.S. funds drawn on a U.S. bank) payable to IBC Life Sciences and attach to the registration form. Confirmation of your booking will be sent. Should you elect to pay by MasterCard, Visa or American Express, please send your credit card number, expiration date, name as it appears on card and signature along with the registration form.

**REGISTRATION SUBSTITUTIONS/CANCELLATIONS:** If you need to make any changes or have any questions, please feel free to contact us via email at reg@ibcusa.com. Cancellations must be in writing and must be received by IBC prior to 10 business days before the start of the event. Upon receipt of a timely cancellation notice, IBC will issue a credit voucher for the full amount of your payment, which may be applied towards registration fees at any future IBC event held within 12 months after issuance (the “Expiration Date”). All credit vouchers will automatically expire on the Expiration Date and shall thereupon become void. In lieu of issuance of a credit voucher, at your request, IBC will issue a refund less a $595 processing fee per registration. Registrants are advised that no credit vouchers or refunds will be issued for cancellations received 10 business days or less prior to the start of the event, including cancellations due to weather or other causes beyond the Registrant’s control. IBC therefore recommends that registrants allow for unexpected delays in making travel plans. Substitutions are welcome at any time. If for any reason IBC decides to cancel this conference, IBC accepts no responsibility for covering airfare, hotel or other costs incurred by registrants, including delegates, sponsors, speakers and guests.

**SPECIAL NEEDS:** If you have a disability or special dietary needs, please let us know in order that we may address your special needs for your attendance at this show. Please send your special needs.

---

**Networking Refreshment Break**

**3:30 Targeting the JAK/STAT Pathway in Solid Tumors with the JAK2 Inhibitor AZD1480**

The identification of the Jak2V617F mutation in the Myeloproliferative Neoplasms resulted in the rapid development of selective Jak kinase inhibitors that are currently undergoing clinical trials in these diseases. Jak kinases are key activators of the STAT family of transcription factors that mediate cytokine and growth factor responses. Persistent activation of STAT3 is oncogenic and has been demonstrated to be prevalent in a wide variety of human cancers. The availability of Jak kinase inhibitors provide a means of testing the involvement of Jak's in Stat3 dependent tumorigenesis and assessing Jak inhibition as a therapeutic point of intervention in tumor indications beyond myeloproliferative neoplasms. Preclinical data on the efficacy of the Jak2 inhibitor AZD1480 in solid tumor models will be presented.

**Dennis Huszar, Ph.D., Principal Scientist II, Translational Science Strategy, Cancer Bioscience, AstraZeneca R&D Boston**

---

**The Pharmacology Audit Trail: Connecting Discovery Research and Clinical Science in Oncology Drug Development**

Oncology drug development in the age of molecularly targeted therapies requires the close integration of laboratory-based scientists and clinical investigators. One approach to improve collaborative decision-making in oncology drug development is the concept of the Pharmacological Audit Trail, first proposed by Workman and colleagues. The audit trail is a sequence of logical assessments examining the pharmacological behavior of an experimental agent. It encompasses evaluations of target expression, pharmacokinetics, pharmacodynamics, and biological and clinical activity in early clinical trials. This approach helps to organize strategic thinking and promotes rational decision making in oncology drug development. At its core is an emphasis on PK/PD model-based drug development. A thorough discussion of the audit trail and its application to the development of targeted oncological therapeutics will be described.

**Chris H. Takimoto, M.D., Ph.D., Senior Director, Translational Medicine, Ortho Biotech Oncology R&D/Center R&D, Inc.**

---

**Strategic Discussion Group**

**Increasing Success in Oncology Drug Development**

- **Can disease models of cancer be improved?**
- **How can preclinical cancer research better support novel approaches to enable patient enrichment/selection, and combination strategies in clinical development?**
- **How can decision-making be improved in phase 2 oncology drug development to avoid phase 3 attrition?**

**Vojo Vukovic, M.D., Ph.D., Vice President, Clinical Research, Synta Pharmaceuticals Corp.**

---

**Close of Conference**

**Thursday, August 6, 2009 (continued)**

---

**Turning Cancer Sequencing Data into Therapeutic Targets**

It has become clear with the advent of high-throughput tumor sequencing projects that large volumes of genome-scale somatic mutation data will soon be generated for hundreds, if not thousands, of tumors. Statistical methods can be applied to detect evidence of positive selection of a mutated gene, but identification of potential therapeutic targets additionally requires functional validation. I will highlight examples of therapeutic targets identified in our cancer sequencing projects and discuss approaches to experimental evaluation of large-scale somatic mutation data.

**Heidi Greulich, Ph.D., Instructor, Dana-Farber Cancer Institute and Visiting Scientist, The Broad Institute of MIT and Harvard**

---

**Effective Use of Animal Models during Preclinical Development of a Vascular Disrupting Agent**

Advancing a cancer drug from preclinical studies into the clinic is a process fraught with challenges, not the least of which is the limited predictive power of animal models. However, such models can still play important roles in understanding drug mechanisms of action, selecting the optimum agent for further development, and validating clinically relevant biomarkers. We will discuss how animal models and bioimaging techniques were used to develop a novel vascular disrupting agent (VDA), STA-9584, which preferentially blocks blood flow in tumors relative to normal tissues, thereby inducing tumor hypoxia and necrosis. Compared to other VDAs, STA-9584 has an improved therapeutic index in preclinical models, and cardiovascular toxicity is predicted not to be dose-limiting.

**Kevin P. Foley, Ph.D., Director, In Vivo Pharmacology, Synta Pharmaceuticals Corp.**

---

**Networking Luncheon with Attendee/Speaker Chat Sessions**

Informal roundtable discussions during the luncheon will be led by conference speakers. Grab your lunch, pick a topic, join a table and meet fellow attendees and conference speakers. Additional topics will be added. See www.drugdisc.com/Cancer for updates. To suggest a discussion topic, e-mail Michael Keenan at mkeenan@ibcusa.com

---

**12:45**

**Group Discounts:** Companies can benefit from significant savings on standard registration fees when registering 3 or more from the same company for any of the 5 so-located conferences. For additional group discount information, please call 617-895-7445.
Explore Next-Generation Technologies, Innovative Solutions & New Ideas in the Exhibit Hall

By attending New Frontiers in Cancer Drug Development conference, you will have the opportunity to accelerate your cancer discovery and development efforts by exploring and evaluating technologies, products and services in the following areas:

- Imaging technologies
- Kinase screening panels and assay services
- Tissue and cell samples
- Cellular analysis/measurement tools
- Label-free technologies
- Molecular diagnostic/Companion diagnostic test kits
- Drug delivery/Nanotechnologies for tumor targeting
- Cancer biomarker development
- Tissue microarrays
- Cancer cell lines
- Stem cell technologies
- In vitro, in vivo, in silico or organ models of cancer

This conference is one of 5 co-located conferences during Drug Discovery & Development Week in Boston (see page 2 for details). A shared exhibit hall featuring over 100 exhibitors will allow you to find products, technologies and services to help accelerate your scientific discoveries.

Exhibit Hall Attractions

As a benefit to your conference registration, we have developed many new attractions in the exhibit hall that will enhance your experience. This year it is not just your typical walk through the exhibit hall. Take part in customized offerings that will allow you the opportunity to collaborate fully on your scientific research.

- **Point-Counterpoint Debate**: find out what technologies are delivering from the end-user perspective, not the vendors
- **Strategic luncheon discussion forums**: determine and debate the pathways that other delegates are taking as part of their R&D strategic approaches
- **“Meet the speakers” networking session**: face to face interaction with the ‘leaders in the industry’ is the most beneficial way to ask follow-up questions and create a valuable dialogue to answer all of your questions and more.
- **Customized tours by topic areas of interest**: join other attendees with similar technology interests and objectives by visiting exhibitors together to enhance your interaction and focus
- **Technology/Service Discounts**: pay for your trip by visiting with exhibitors offering discounts and giveaways

For more information on the exhibit hall or any of the conferences held during Drug Discovery & Development week, visit www.drugdisc.com.

**Sponsors**

**Gold, Presentation, and Totebag Sponsor**

Roche

Roche Applied Science provides complete solutions for drug discovery research, including instruments, reagents, and software. Instruments include the next generation Genome Sequencer FLX System, the new MagnaPure 96 for automated nucleic acid isolation of 96 samples in less than an hour, the LightCycler® 480 Real-Time PCR Instrument (96 or 384 well) and the new Lightcycler 1536 (1536 well) Real-time PCR instrument, NimbleGen microarrays with 2.1 million features, and the new xCELLigence Real-time, Label-free cell analysis instrument.

**Technology Workshop Sponsor**

MDS Pharma Services

**Sponsoring Publications**

ddn, nature, AAAS

**Media Partners**

cancer Drug News, DDW, GCP, MedTRACK, TheScientist

**Exhibit and Sponsorship Opportunities**

at New Frontiers in Cancer Drug Development Conference

By sponsoring or exhibiting, you will meet a group of targeted potential buyers who are interested in accelerating their discovery and development efforts. IBC will assist you in meeting all of your company objectives pre-event, onsite and post-event.

**Sponsorships currently available include:**

- Technology Workshops
- Badge and Lanyards
- Conference Sessions
- Receptions
- Refreshment Breaks
- Webinars

For more information on exhibiting or sponsoring at this event, please contact

Sherry Johnson, Tel: 508-614-1451,
E-mail: sjohnson@ibcusa.com

Kristen Schott, Phone 508-614-1239,
E-mail: kschott@ibcusa.com

Visit www.drugdisc.com/Cancer for up-to-date information on this event

5 Conferences 1 Exhibition

**Exhibitors** (as of March 20, 2009)

<table>
<thead>
<tr>
<th>Sponsor Name</th>
<th>Technology/Service Discounts</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABS Inc</td>
<td></td>
</tr>
<tr>
<td>Accelrys</td>
<td></td>
</tr>
<tr>
<td>Agilent Technologies</td>
<td></td>
</tr>
<tr>
<td>AMG-Advanced Microscopy Group</td>
<td></td>
</tr>
<tr>
<td>Aperio</td>
<td></td>
</tr>
<tr>
<td>Baxter</td>
<td></td>
</tr>
<tr>
<td>Beckman Coulter, Inc.</td>
<td></td>
</tr>
<tr>
<td>Biodirect</td>
<td></td>
</tr>
<tr>
<td>Blohit, Inc.</td>
<td></td>
</tr>
<tr>
<td>BioTek</td>
<td></td>
</tr>
<tr>
<td>BMG LABTECH</td>
<td></td>
</tr>
<tr>
<td>Caliper Life Sciences</td>
<td></td>
</tr>
<tr>
<td>CambridgeSoft</td>
<td></td>
</tr>
<tr>
<td>CAS</td>
<td></td>
</tr>
<tr>
<td>CEM</td>
<td></td>
</tr>
<tr>
<td>Crown Bioscience Inc.</td>
<td></td>
</tr>
<tr>
<td>DeltaSoft, Inc.</td>
<td></td>
</tr>
<tr>
<td>Enamine</td>
<td></td>
</tr>
<tr>
<td>Essen Instruments</td>
<td></td>
</tr>
<tr>
<td>Eurogentec</td>
<td></td>
</tr>
<tr>
<td>Formulatrix</td>
<td></td>
</tr>
<tr>
<td>GE Healthcare</td>
<td></td>
</tr>
<tr>
<td>GENEWIZ, Inc.</td>
<td></td>
</tr>
<tr>
<td>Hamilton Company</td>
<td></td>
</tr>
<tr>
<td>IXC Nomadics</td>
<td></td>
</tr>
<tr>
<td>Integrated DNA Technologies</td>
<td></td>
</tr>
<tr>
<td>KINOMEscan</td>
<td></td>
</tr>
<tr>
<td>Life Chemicals, Inc.</td>
<td></td>
</tr>
<tr>
<td>Maccine Pte Ltd</td>
<td></td>
</tr>
<tr>
<td>Millipore</td>
<td></td>
</tr>
<tr>
<td>Molecular Devices</td>
<td></td>
</tr>
<tr>
<td>(now part of MDS Analytical Technologies)</td>
<td></td>
</tr>
<tr>
<td>Omni International - The Homogenizer Company</td>
<td></td>
</tr>
<tr>
<td>Pall Life Sciences</td>
<td></td>
</tr>
<tr>
<td>Paragon Bioservices, Inc.</td>
<td></td>
</tr>
<tr>
<td>Peakdale Molecular Ltd.</td>
<td></td>
</tr>
<tr>
<td>Quotient Bio recherche</td>
<td></td>
</tr>
<tr>
<td>Roche Applied Science</td>
<td></td>
</tr>
<tr>
<td>Shanghai Mediclon</td>
<td></td>
</tr>
<tr>
<td>Sigma-Aldrich</td>
<td></td>
</tr>
<tr>
<td>Specs</td>
<td></td>
</tr>
<tr>
<td>Teledyne Isco</td>
<td></td>
</tr>
<tr>
<td>TITian Software</td>
<td></td>
</tr>
<tr>
<td>Toxikon</td>
<td></td>
</tr>
<tr>
<td>TTP LabTech</td>
<td></td>
</tr>
<tr>
<td>V &amp; P Scientific, Inc.</td>
<td></td>
</tr>
<tr>
<td>Viva Biotech</td>
<td></td>
</tr>
</tbody>
</table>

For an updated list of exhibiting companies, visit www.drugdisc.com
New Frontiers in Cancer Drug Development
Innovations in Discovery Science, Translational Research and Cancer Clinical Trials

By Attending, You will...

- Listen to the latest information from companies developing therapeutics based on cancer stem cell research.
- Learn about the regulatory pathway and FDA position on biomarkers and companion diagnostics for cancer.
- Evaluate data emerging from exciting cancer targets/pathways and cancer epigenetic studies.
- Hear the latest clinical results of combinations of molecular targeted cancer agents.

Register today at www.drugdisc.com/Cancer

Industry Fees

<table>
<thead>
<tr>
<th>Industry Type</th>
<th>By May 8, 2009</th>
<th>By June 5, 2009</th>
<th>By July 10, 2009</th>
<th>Standard Rate After July 10, 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Drug Development Main Conference (Wed.-Thur.)</td>
<td>$1599</td>
<td>$1699</td>
<td>$1799</td>
<td>$1899</td>
</tr>
<tr>
<td>Add Pre-Conference Workshop (Tuesday)</td>
<td>$299</td>
<td>$299</td>
<td>$299</td>
<td>$299</td>
</tr>
<tr>
<td>All-Access Conference Pass (Pass includes full access to all five co-located conferences and workshops)</td>
<td>$2499</td>
<td>$2599</td>
<td>$2699</td>
<td>$2799</td>
</tr>
<tr>
<td>Networking Dinner (Wednesday)</td>
<td>Industry $75</td>
<td>Academic $75</td>
<td>Industry $75</td>
<td>Academic $75</td>
</tr>
</tbody>
</table>

Academic/Government Special Rates:
Academic and government employees are eligible for over 40% savings off the above registration packages. Visit the registration page at www.drugdisc.com for packages, pricing and to register. Academic/Government rate is extended to full-time employees of government, universities, and university-affiliated hospitals only.

For security precautions, a photo identification will be required of ALL attendees at check-in. For on-site registration, please add $100 to the total fee. Price for main conference includes lunch, refreshments and speaker documentation. See inside for policies regarding Substitutions, Cancellations and Special Needs.

Unable to Attend? Purchase the Conference Materials.
Conference materials including a selection of speaker presentations will be available for purchase following the event. I cannot attend and would like to purchase the conference materials. Enclosed is my payment for $399 (fee does not include shipping and handling, when applicable).

Payment
(Required 30 days in advance of the conference. If registering within 30 days, payment is due immediately)

- Mastercard
- Visa
- American Express
- Check
- Wire Transfer

Please make check(s) (in U.S. funds drawn on a U.S. bank) payable to IBC USA Conferences and attach to the registration form. Confirmation of your booking will be sent. Wire Transfer: Please tell your bank to include the conference code, invoice number, person attending, name and date of the conference in the transfer instructions. Wire transfers and EFT payments: please contact accounts receivable at Account-liaison@informausa.com for banking details.

Card #
Exp. Date
CVV Code

Name (as appears on card)

Signature